ArisGlobal Signs European Commission’s AI Pact

Boston-based ArisGlobal announced on Feb. 12, 2025 that it has signed the AI Pact, a voluntary framework created by the European Commission (EC) for stakeholders to prepare for the European Union (EU)’s implementation of its AI Act (1). The AI Pact, according to a press release from ArisGlobal, is the first comprehensive regulation of artificial intelligence (AI) worldwide by a major regulator.

“At ArisGlobal, we believe that AI should benefit society, which isn’t possible without ethical AI practices,” Jason Bryant, ArisGlobal vice-president of product management for AI & Data, said in the press release (1). “We take responsible AI very seriously. That is both via our leadership position in the industry, and as we apply the technology to deliver advanced insight—allowing our customers to make better decisions that feed into patient safety. Joining the AI Pact reinforces our commitment, and our belief in a future underpinned by responsible AI.”

The public pledge to which signees of the AI Pact commit is centered on responsible, ethical AI development and deployment and implies a commitment to upholding the utmost standards and best practices pertaining to AI governance (1).

ArisGlobal said customers of its LifeSphere Regulatory and Safety platform, powered by the NavaX cognitive computing engine, were top of mind in the decision to sign the pledge.

The AI Pact also charges signees with performing high-risk AI systems mapping—in other words, identifying systems likely to be considered high-risk under the AI Act—and sharing AI literacy and awareness with companies’ staff members.

“Our progress will be as visible as our commitment,” Bryant said. “We will report on our performance against our core promises, as well as additional approaches we’ll be taking to drive best-of-breed industry behavior.”

Ramesh Ramani, vice-president of technology, and RaviKanth Valigari, vice-president of product development, previously elaborated on ArisGlobal’s outlook on AI standards compliance in a July 2024 piece on PharmTech.com.

“Responsible AI and AI compliance are particularly critical in life sciences-use cases, so it is essential that companies deploy solutions that are proven and transparent,” Ramani and Valigari wrote in the article (2). “The LLM [large language model]/RAG [retrieval-augmented generation] approach addresses potential concerns about data security and privacy, too, as it does not require the use of potentially sensitive patient data for algorithm training and ML [machine learning]. It also stands up to validation by way of periodic sampling by human team members, sampling which can be calibrated as confidence grows in the technology’s performance, ensuring that efforts to monitor its integrity do not undermine the significant efficiency gains that are possible” (2).

To help mark the 10th anniversary of International Day of Women and Girls in Science, PharmTech.com interviewed Agnes Cwienczek, director of Product Management at ArisGlobal, who said women’s contributions to the use of AI in pharma have included emotional intelligence, creativity, critical thinking, and problem solving (3).

“While some of these are perhaps less directly relevant to defining and developing AI-based solutions, they can be important to the implementation of those solutions within an organization,” Cwienczek said.

More of PharmTech.com’s coverage of International Day of Women and Girls in Science 2025, as it pertains to AI, can be found here, and here.

References

1. ArisGlobal. ArisGlobal Signs EU AI Pact in Latest Commitment to Ethical AI Practices. Press Release. Feb. 12, 2025.
2. Ramani, R. and Valigari, R. Beyond GenAI: The Training-Free Discovery Potential of LLMs in a Drug Safety and Regulatory Context. PharmTech.com, July 1, 2024.
3. Haigney, S. Women, STEM, and AI in Pharma. PharmTech.com, Feb. 11, 2025.